Table 1.
Patient demographics and characteristics in Cohort 1.
| Original data | Data after propensity score matching | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Second-line chemotherapy n = 156 | BSC n = 77 | P | SMD | Second-line chemotherapy n = 98 | BSC n = 61 | P | SMD | ||
| Age (years) | Years, median (range) | 64 (35–86) | 66 (39–86) | 0.03 | 0.28 | 64 (35–86) | 66 (39–78) | 0.34 | 0.15 |
| Sex, n (%) | Male | 91 (58) | 51 (66) | 0.25 | 0.16 | 55 (56) | 41 (67) | 0.16 | 0.23 |
| Female | 65 (42) | 26 (34) | 43 (44) | 20 (33) | |||||
| ECOG PS, n (%) | 0 | 110 (71) | 35 (45) | < 0.01 | 0.56 | 60 (61) | 35 (57) | 0.75 | 0.19 |
| 1 | 39 (25) | 33 (43) | 31 (32) | 23 (38) | |||||
| ≥ 2 | 7 (4) | 9 (12) | 7 (7) | 3 (5) | |||||
| Previous surgical resection, n (%) | 19 (12) | 18 (23) | 0.03 | 0.30 | 16 (16) | 13 (21) | 0.43 | 0.13 | |
| Tumor location, n (%) | Head | 74 (47) | 37 (48) | 0.82 | 0.09 | 46 (47) | 29 (48) | 0.84 | 0.1 |
| Body | 48 (31) | 21 (27) | 31 (32) | 17 (28) | |||||
| Tail | 34 (22) | 19 (25) | 21 (21) | 15 (25) | |||||
| Histology, n (%) | Adenocarcinoma | 136 (87) | 60 (78) | 0.10 | 0.28 | 86 (88) | 46 (75) | 0.11 | 0.34 |
| Others | 2 (1) | 4 (5) | 2 (2) | 4 (7) | |||||
| Unknown | 18 (12) | 13 (17) | 10 (10) | 11 (18) | |||||
| Number of metastatic sites, n (%) | 1 | 97 (62) | 44 (57) | 0.46 | 0.10 | 60 (61) | 36 (59) | 0.78 | 0.05 |
| ≥ 2 | 59 (38) | 33 (43) | 38 (39) | 25 (41) | |||||
| Ascites, n (%) | 29 (19) | 23 (30) | 0.052 | 0.27 | 19 (19) | 13 (21) | 0.77 | 0.05 | |
| Albumin level (g/dL) | Median (range) | 3.9 (2.5–4.8) | 3.6 (2.2–4.8) | < 0.01 | 0.50 | 3.9 (2.5–4.8) | 3.7 (2.2–4.8) | 0.11 | 0.28 |
| LDH level (U/L) | Median (range) | 176 (99–923) | 194 (74–1320) | 0.02 | 0.24 | 178 (122–723) | 195 (74–1320) | 0.12 | 0.24 |
| CRP level (mg/dL) | Median (range) | 0.28 (0.01–8.88) | 0.90 (0.01–17.00) | 0.02 | 0.39 | 0.42 (0.01–8.88) | 0.86 (0.01–15.80) | 0.27 | 0.30 |
| CEA level (ng/mL) | Median (range) | 5.4 (0.4–626.6) | 7.0 (0.8–369.8) | 0.16 | 0.07 | 5.4 (0.4–626.6) | 7.4 (0.8–164.3) | 0.25 | 0.19 |
| CA19-9 level (U/mL) | Median (range) | 1122 (1–6,554,100) | 835 (1–4,690,400) | 0.94 | 0.02 | 1287 (1–6,554,100) | 752 (1–277,056) | 0.87 | 0.16 |
| Neutrophil-to-lymphocyto ratio | Median (range) | 2.05 (0.09–15.17) | 2.61 (0.24–21.96) | 0.09 | 0.25 | 2.31 (0.09–15.17) | 2.61 (0.36–21.96) | 0.69 | 0.05 |
| First-line chemotherapy, n (%) | FFX | 79 (51) | 15 (19) | < 0.01 | 0.69 | 34 (35) | 15 (25) | 0.18 | 0.22 |
| GnP | 77 (49) | 62 (81) | 64 (65) | 46 (75) | |||||
| Withdrawal reason, n (%) | Progression | 137 (88) | 55 (71) | < 0.01 | 0.42 | 83 (85) | 46 (75) | 0.35 | 0.23 |
| Adverse events | 16 (10) | 18 (23) | 12 (12) | 12 (20) | |||||
| Others | 3 (2) | 4 (5) | 3 (3) | 3 (5) | |||||
| Duration of first-line chemotherapy | Months, median (range) | 5.6 (0.4–30.8) | 3.5 (0.2–22.2) | 0.02 | 0.23 | 4.8 (0.4–19.8) | 3.6 (0.2–22.2) | 0.28 | 0.06 |